Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan.

Summary

• Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 13 shares of common stock on February 20, 2024.
• The shares were acquired at a price of $755.66 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Johnson's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director alignment with company performance. It is not a major event, hence the moderate score.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine transaction for a director of a public company, often part of their compensation package.

Comparison to Industry Standards

• Director share acquisitions are common across the pharmaceutical industry, often as part of deferred compensation plans.
• Many companies, such as Pfizer (PFE) and Johnson & Johnson (JNJ), have similar director compensation structures that include stock awards or deferral plans.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with company performance.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, LLY, Kimberly H. Johnson